Aussie digital health company announces V2 of respiratory diagnostic smartphone test
Australian digital health company ResApp Health Limited has received approval for the latest version of the world’s first smartphone-based diagnostic test for respiratory disease for both adults and children. This extends existing approval and adds the ability to test adults for lower respiratory tract disease, pneumonia, asthma exacerbation and chronic obstructive pulmonary disease exacerbation. This certification also allows the sale of this app throughout the European Economic Area. | http://bit.ly/33boyLp
Congenital heart disease (CHD) is the leading cause of death and hospitalisation in infants, affecting one in 100 births. The potential for a genetic link to the condition is now being explored in a new Australian Genomics study supported by HeartKids.So far advanced genetic testing could potentially identify the cause of conditions in up to 50% of families, helping to improve diagnosis, provide better treatment and management outcomes as well as early diagnosis of CHD. 200 families affected by CHD are urged to participate in the study to help researchers.Visit Heartkids for more information!